Company intelligence / Profile preview
Cantabio Pharmaceuticals
Palo Alto, California, United Statescantabio.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Preclinical
01
Overview
Cantabio is developing novel therapeutics for neurodegenerative and metabolic diseases. Their pipeline includes multiple pre-clinical candidates targeting DJ-1 and Tau proteins. No clinical trials have been initiated yet.
- Therapeutic areas
- EndocrinologyNeurology
- Modalities
- Small moleculesCell-penetrant proteinsTherapeutic proteins
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
University of CambridgeNovALiX
Beyond the preview
Go deeper on Cantabio Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cantabio Pharmaceuticals.